Search results for "REDUCTASE"

showing 10 items of 798 documents

Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision

2008

OBJECTIVE: To assess whether the prescribing pattern of lipid-lowering drugs (LLD) changed after reimbursement criteria revision in a general practice in southern Italy. METHODS: From the Caserta-1 Local Health Service database, 93 general practitioners (GPs) who had consistently sent data about their patients during the years 2003-2005 were recruited. Prevalence of use and incidence of new treatments were calculated for each year, stratified by three drug cohorts: statins, omega-3 fatty acids, and fibrates. Subanalyses by gender, age, and indication of use were performed. RESULTS: Overall, 1-year prevalence of LLD use increased from 2003 to 2004. After reimbursement criteria revision (Nove…

Drug Utilizationmedicine.medical_specialtyPediatricsStatinSettore MED/09 - Medicina Internamedicine.drug_classMEDLINEstatinsInternal medicineFatty Acids Omega-3EpidemiologyHumansMedicinePharmacology (medical)RosuvastatinLipid-lowering drug Statins Omega-3 fatty acids Prevalence of use General practiceClofibrateReimbursementUnsaturated fatty acidHypolipidemic AgentsPharmacologygeneral practiceprevalence of usePrimary Health Careomega-3 fatty acidsbusiness.industryIncidence (epidemiology)General Medicinelipid-lowering drugSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheDrug UtilizationItalyInsurance Health ReimbursementSettore BIO/14 - FarmacologiaHydroxymethylglutaryl-CoA Reductase Inhibitorslipid-lowering drug; statins; omega-3 fatty acids; prevalence of use; general practicebusinessmedicine.drug
researchProduct

Combined pharmacological treatment of heterozygous familial hypercholesterolemia

1990

Combined therapy of heterozygous familial hypercholesterolemia using a non-systemically acting drug (bile acid sequestrants) and a systemically acting one is frequently employed in clinical practice. A brief review of this topic is presented, with particular emphasis on the use of cholestyramine combined with pravastatin, a new HMG CoA reductase inhibitor.

DrugCholestyramineBile acidbiologymedicine.drug_classbusiness.industrymedia_common.quotation_subjectnutritional and metabolic diseasesFamilial hypercholesterolemiaMevalonic acidPharmacologymedicine.diseasePharmacological treatmentchemistry.chemical_compoundchemistryHMG-CoA reductasemedicinebiology.proteinbusinessPravastatinmedicine.drugmedia_common
researchProduct

Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain.

2019

Abstract Background Drug treatment for secondary prevention of cardiovascular disease is recommended by guidelines, but it is not always followed in real life. This study wanted to assess the size of this gap and its impact on mortality in subjects after a cardiovascular event (MACE). Methods Patients with any of MACE in the period from January 1st 2011 to December 31st 2013, and more than one year of follow-up were selected from population of the Valencian Community. Drugs for secondary prevention were antiplatelets, renin-angiotensin system blockers and statins. Assessment of treatment was performed one year after the initial event. Mortality risk was assessed using Cox by the number of d…

DrugMalemedicine.medical_specialtyMedication Therapy Managementmedia_common.quotation_subjectmedicine.medical_treatmentPopulationMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsDisease030204 cardiovascular system & hematologyRevascularizationRisk Assessment03 medical and health sciencesAngiotensin Receptor Antagonists0302 clinical medicineInternal medicinemedicineSecondary PreventionHumans030212 general & internal medicineMyocardial infarctioneducationStrokemedia_commonAgededucation.field_of_studybusiness.industryConfoundingmedicine.diseaseSurvival AnalysisProfessional Practice GapsStrokeSpainFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessMacePlatelet Aggregation InhibitorsInternational journal of cardiology
researchProduct

An overview of statin-induced myopathy and perspectives for the future

2020

Introduction: Statins remain the most commonly prescribed lipid-lowering drug class for the treatment of atherosclerotic cardiovascular disease. Their well-recognized side effects are known as statin-associated muscle symptom (SAMS). Some advances in this field have been made in recent years, but the understanding of the mechanisms has lagged. Investigating the specific role of the anti-HMGCR autoantibody, pharmacokinetic genetic variants, characterization of the known phenotypes of statin toxicity, in relation to clinical markers of disease, is of high importance. Areas covered: We summarized currently available findings (on PubMed) related to SAMS and discussed the therapeutic approaches,…

DrugStatinUbiquinonemedicine.drug_classmedia_common.quotation_subjectHyperlipidemiasDiseasetherapeutic approaches030204 cardiovascular system & hematologyBioinformaticsPharmacogenomic Variants03 medical and health sciences0302 clinical medicineMuscular DiseasesRisk FactorsmedicineAnimalsHumansDrug InteractionsPharmacology (medical)Adverse effectHypolipidemic Agentsmedia_commondrug interactionbusiness.industryGeneral MedicineAtherosclerosisStatin induced myopathystatin-induced myopathyunderlying mechanismDrug classrisk factor030220 oncology & carcinogenesisCoenzyme Q10Hydroxymethylglutaryl-CoA Reductase Inhibitorsmyositis autoantibodieRisk assessmentbusinessstatin-associated muscle symptom
researchProduct

Drug-metabolizing enzymes in the skin of man, rat, and pig.

2007

The mammalian skin has long been considered to be poor in drug metabolism. However, many reports clearly show that most drug metabolizing enzymes also occur in the mammalian skin albeit at relatively low specific activities. This review summarizes the current state of knowledge on drug metabolizing enzymes in the skin of human, rat, and pig, the latter, because it is often taken as a model for human skin on grounds of anatomical similarities. However only little is known about drug metabolizing enzymes in pig skin. Interestingly, some cytochromes P450 (CYP) have been observed in the rat skin which are not expressed in the rat liver, such as CYP 2B12 and CYP2D4. As far as investigated most d…

Drugcytochrome P450Swinemedia_common.quotation_subjectMetaboliteAldehyde dehydrogenaseHuman skinEpoxide hydrolaseEsterasechemistry.chemical_compoundOrgan Culture TechniquesCytochrome P-450 Enzyme SystemSpecies SpecificityGlycosyltransferaseAnimalsHumansPharmacology (medical)ratGeneral Pharmacology Toxicology and PharmaceuticsFlavin monooxygenaseCells Culturedmedia_commonSkinchemistry.chemical_classificationquinone reductase [NAD(P)H]biologyintegumentary systemAlcohol dehydrogenaseSulfotransferaseCytochrome P450Aldehyde dehydrogenaseMetabolic Detoxication Phase IIEnzymesRatsGlutathione S-transferaseIsoenzymesEnzymechemistryBiochemistryPharmaceutical PreparationsN-acetyltransferasebiology.proteinMetabolic Detoxication Phase IPig skin drug metabolismDrug metabolismUDP-glucuronosyltransferaseHuman
researchProduct

Adverse drug reaction and organ damage: the liver

2016

Drug-induced liver injury (DILI) is among the most challenging acute or chronic liver conditions to be handled by physicians. Despite its low incidence in the general population, DILI is a frequent cause of acute liver failure. As such, the possibility of DILI should be considered in all patients who present with acute liver damage, independent of any known pre-existing liver disease. DILI can be classified as intrinsic/dose-dependent (e.g., acetaminophen toxicity) or idiosyncratic/dose-independent, with the latter form being relatively uncommon. Amoxicillin-clavulanate is the antimicrobial that is most frequently associated with idiosyncratic DILI. Large, ongoing, prospective studies in we…

Drugmedicine.medical_specialtySettore MED/09 - Medicina InternaClinical presentationEpidemiologymedia_common.quotation_subjectPopulation03 medical and health sciencesLiver disease0302 clinical medicineRisk FactorsEpidemiologyInternal MedicinemedicineHumansRisk factorIntensive care medicineeducationmedia_commonLiver injuryeducation.field_of_studybusiness.industryIncidenceAnti-Inflammatory Agents Non-SteroidalBiomarkers; Clinical presentation; Diagnosis; Drug induced liver injury; Epidemiology; Risk factorBiomarkermedicine.diseaseDrug development030220 oncology & carcinogenesisDietary Supplements030211 gastroenterology & hepatologyPlant PreparationsDrug induced liver injuryRisk factorChemical and Drug Induced Liver InjuryHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPharmacogeneticsDiagnosi
researchProduct

LDL and HDL subfractions, dysfunctional HDL: treatment options.

2014

Low-density lipoproteins (LDL) are considered as important risk factors for cardiovascular diseases (CVD), while highdensity lipoproteins (HDL) are well recognized for their putative role in reverse cholesterol transport and other atheroprotective functions. Both LDL and HDL are heterogeneous in nature, including various subfractions depending on the method of isolation (≥ 7 LDL and 10 HDL subspecies, respectively). While it is established that small, dense LDL (sdLDL) have atherogenic potential, the role of different HDL subfractions is still largely unclear. The majority of clinical studies suggest an atheroprotective role of larger HDL particles, although recent work has highlighted the…

Drugmedicine.medical_specialtymedia_common.quotation_subjectDysfunctional familychemistry.chemical_compoundRisk FactorsInternal medicineDrug DiscoveryCholesterylester transfer proteinmedicineHumansmedia_commonPharmacologybiologybusiness.industryCholesterolReverse cholesterol transportnutritional and metabolic diseasesLipoproteins LDLResidual riskEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Hdl subfractionsHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins HDLbusinessNiacin
researchProduct

Echovirus 1 Entry into Polarized Caco-2 Cells Depends on Dynamin, Cholesterol, and Cellular Factors Associated with Macropinocytosis

2013

ABSTRACT Enteroviruses invade their hosts by crossing the intestinal epithelium. We have examined the mechanism by which echovirus 1 (EV1) enters polarized intestinal epithelial cells (Caco-2). Virus binds to VLA-2 on the apical cell surface and moves rapidly to early endosomes. Using inhibitory drugs, dominant negative mutants, and small interfering RNAs (siRNAs) to block specific endocytic pathways, we found that virus entry requires dynamin GTPase and membrane cholesterol but is independent of both clathrin- and caveolin-mediated endocytosis. Instead, infection requires factors commonly associated with macropinocytosis, including amiloride-sensitive Na + /H + exchange, protein kinase C, …

DynaminsSodium-Hydrogen ExchangersEndosomeImmunologyEndocytic cycleEndocytosisMicrobiologyClathrinViral entryVirologyHumansTransport VesiclesProtein Kinase CDynaminbiologyPinocytosisEpithelial CellsVirus InternalizationIntestinal epitheliumEnterovirus B HumanVirus-Cell InteractionsCell biologyDNA-Binding ProteinsAlcohol OxidoreductasesCholesterolInsect ScienceHost-Pathogen Interactionsbiology.proteinPinocytosisCaco-2 CellsJournal of Virology
researchProduct

Cytokinin affects nitrate reductase expression through the modulation of polyadenylation of the nitrate reductase mRNA transcript

1993

Abstract Cytokinin (CK) and low-intensity light effects in modulating nitrate reductase (NR) activity, NR protein and NR encoding mRNAs were studied in tobacco cell suspension cultures. NR activity was strikingly enhanced by CK in dark- as well as in light-grown cells whereas it was less affected by light alone. NR protein accumulation was stimulated by the hormone in the light only; then a CK light-dependent regulation of NR activity was suggested. Light enhanced the steady-state levels of hybridisable total NR mRNA and a light-inductive effect was also observed after transfer from dark to light; this effect was dependent on sucrose supply and was enhanced in CK-supplied cells. NR poly(A) …

EXPRESSION0106 biological sciencesPolyadenylationPlant ScienceBiologyNitrate reductase01 natural sciences[SDV.GEN.GPL]Life Sciences [q-bio]/Genetics/Plants genetics03 medical and health scienceschemistry.chemical_compoundMRNA polyadenylation[SDV.GEN.GPL] Life Sciences [q-bio]/Genetics/Plants geneticsGene expressionGeneticsComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesMessenger RNARNAGeneral MedicineMolecular biologyBiochemistrychemistryCell culturePMSFAgronomy and Crop Science010606 plant biology & botanyPlant Science
researchProduct

Guava (Psidium guajava L.) Leaf Extract as Bioactive Substances for Anti-Androgen and Antioxidant Activities

2022

Leaves of guava (Psidium guajava L.) have been used in Thai folk medicine without any supporting evidence as a traditional herbal remedy for hair loss. Androgenetic alopecia (AGA) is chronic hair loss caused by effects of androgens in those with a genetic predisposition, resulting in hair follicle miniaturization. Our objectives were to provide the mechanistic assessment of guava leaf extract on gene expressions related to the androgen pathway in well-known in vitro models, hair follicle dermal papilla cells (HFDPC), and human prostate cancer cells (DU-145), and to determine its bioactive constituents and antioxidant activities. LC-MS analysis demonstrated that the main components of the et…

EcologyPlant SciencePlantes medicinalsEcology Evolution Behavior and Systematicsandrogenetic alopecia; anti-hair loss; dermal papilla; DU-145; guava; hair follicle; hair growth; HFDPC; 5α-reductase; <i>SRD5A</i>Plants; Volume 11; Issue 24; Pages: 3514
researchProduct